Structural determinants of dual incretin receptor agonism by tirzepatide

Bingfa Sun1, Francis S. Willard1,1, Dan Feng1,1, Jorge Alsina-Fernandez2, Qi Chen1,4, Michael Vieth3, Joseph D. Ho1, Aaron D. Showalter1, Cynthia Stutsman1, Liyun Ding3, Todd M. Suter1, James D. Dunbar1, John W. Carpenter1, Faiz Ahmad Mohammed4, Eitaro Aihara1, Robert A. Brown1, Ana B. Bueno5, Paul J. Emmerson1, Julie S. Moyers1, Tong Sun Koblika6, Matthew P. Coghlan6, Brian K. Kobilka1,2, and Kyle W. Sloopf2

Edited by Eric Xu, Shanghai Institute of Materia Medica, Shanghai, China; received September 10, 2021; accepted January 31, 2022 by Editorial Board Member David J. Mangelsdorf

Tirzepatide (LY3298176) is a fatty-acid-modified, dual incretin receptor agonist that exhibits pharmacology similar to native GIP at the glucose-dependent insulinotropic polypeptide receptor (GIPR) but shows bias toward cyclic adenosine monophosphate signaling at the glucagon-like peptide-1 receptor (GLP-1R). In addition to GIPR signaling, the pathway bias at the GLP-1R may contribute to the efficacy of tirzepatide at improving glucose control and body weight regulation in type 2 diabetes mellitus. To investigate the structural basis for the differential signaling of tirzepatide, mechanistic pharmacology studies were allied with cryogenic electron microscopy. Here, we report high-resolution structures of tirzepatide in complex with the GIPR and GLP-1R. Similar to the native ligands, tirzepatide adopts an α-helical conformation with the N terminus reaching deep within the transmembrane core of both receptors. Analyses of the N-terminal tyrosine (Tyr1Tzp) of tirzepatide revealed a weak interaction with the GLP-1R. Molecular dynamics simulations indicated a greater propensity of intermittent hydrogen bonding between the lipid moiety of tirzepatide and the GIPR versus the GLP-1R, consistent with a more compact tirzepatide–GIPR complex. Informed by these analyses, tirzepatide was deconstructed, revealing a peptide structure–activity relationship that is influenced by acylation-dependent signal transduction. For the GIPR, Tyr1Tzp and other residues making strong interactions within the receptor core allow tirzepatide to tolerate fatty acid modification, yielding an affinity equaling that of GIP. Conversely, high-affinity binding with the extracellular domain of the GLP-1R, coupled with decreased stability from the Tyr1Tzp and the lipid moiety, foster biased signaling and reduced receptor desensitization. Together, these studies inform the structural determinants underling the function of tirzepatide.

G protein coupled receptor (GPCR) | structure | tirzepatide | GIP receptor | GLP-1 receptor

Designing therapeutic ligands capable of targeting multiple receptor systems offers opportunities to discover more effective treatments for complex diseases, especially for conditions where intervening at more than one signaling pathway may be beneficial. One such molecule is tirzepatide (LY3298176), a 39-amino acid linear peptide possessing agonist activity at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) (1, 2). The dual agonist nature of this molecule represents a promising therapeutic modality for the treatment of metabolic disorders, such as type 2 diabetes mellitus (T2DM), obesity (including heart failure patients with preserved ejection fraction), and nonalcoholic steatohepatitis. This therapeutic approach is founded on the established clinical efficacy of selective GLP-1R agonists, with the bifunctional concept being informed by the hypothesis that concerted activation of both receptors improves glucose control, energy balance, and lipid storage (3, 4). In addition to the dual pharmacology, maintaining efficacious concentrations of the drug is important for maximizing the benefit of this type of treatment. Therefore, to sustain the actions of tirzepatide, the peptide is conjugated through a lysine located near the middle of the molecule to a C20 fatty diacid moiety via a hydrophilic linker (2). This fatty acid modification enables reversible, noncovalent binding to human serum albumin and thus contributes to a pharmacokinetic profile that enables once-weekly dosing of the drug (1).

To date, the clinical development program for tirzepatide has yielded encouraging results, highlighted by data showing improvements in glycemic control and energy metabolism. The efficacy of tirzepatide to effectively lower glucose and body weight in subjects with T2DM was established in a 26-wk phase 2b trial (5). Moreover, post hoc analyses of this trial reported that treatment with tirzepatide demonstrated favorable effects on markers of insulin sensitivity and pancreatic beta cell function and also

Significance

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), which are incretin receptors that regulate carbohydrate metabolism. This investigational agent has proven superior to selective GLP-1R agonists in clinical trials in subjects with type 2 diabetes mellitus. Intriguingly, although tirzepatide closely resembles native GIP in how it activates the GIPR, it differs markedly from GLP-1 in its activation of the GLP-1R, resulting in less agonist-induced receptor desensitization. We report how cryogenic electron microscopy and molecular dynamics simulations inform the structural basis for the unique pharmacology of tirzepatide. These studies reveal the extent to which fatty acid modification, combined with amino acid sequence, determines the mode of action of a multireceptor agonist.
reduced atherogenic lipid particles (6, 7). Interestingly, the improvement in insulin sensitivity appeared largely independent of changes in body weight (6). These data supported the initiation of a phase 3 clinical development program for tirzepatide, known as SURPASS (8), and in particular, the results reported from SURPASS-2, a 40-wk pivotal trial in subjects with T2DM, indicate the benefit of dual GIP/GLP-1 pharmacology (9). In this head-to-head study against the highest dose of the GLP-1R monoanagonist semaglutide that is currently approved, all three doses of tirzepatide delivered superior glucose and weight reductions. The superior clinical efficacy of tirzepatide points to the advantage of adding GIP pharmacology to GLP-1 therapy.

Due to the clinical data, determining the mechanisms responsible for the improvement in metabolic control that occur upon treatment with tirzepatide is an area of active investigation. Ex vivo assays using islets isolated from Gipr or Glp-1r knockout mice and glucose tolerance tests performed in both of these models demonstrate that tirzepatide can enhance insulin secretion and reduce hyperglycemia through either receptor (1). Pharmacologically, receptor-specific cyclic adenosine monophosphate (cAMP) accumulation assays show tirzepatide is an imbalanced agonist favoring GIP over GLP-1R activity; these results align with binding data indicating the affinity of tirzepatide for the GIPR is equal to that of GIP but approximately fivefold weaker than GLP-1 on the GLP-1R (1, 10). The benefit of strong GIPR activity is supported by findings from studies showing that GIPR agonism improves insulin sensitivity by a mechanism independent of weight loss (11). Furthermore, an intact GIP axis in the brain is necessary to achieve the full anorexigenic effect of dual GIPR and GLP-1R agonist treatment (12). In line with both of these findings, the expression of the GIPR in adipose tissue and certain metabolic control centers in the brain likely contribute to the benefit of the GIP component of tirzepatide (3).

At the same time, studies characterizing the pharmacology of tirzepatide at the GLP-1R have garnered attention by showing that it displays pathway bias for cAMP signaling over β-arrestin recruitment (10, 13). The significance of this finding is not fully realized but may be substantive in light of reports showing biased recruitment (10, 13). The signifi-

component of tirzepatide (3).

centers in the brain likely contribute to the bene-
cy and potency properties at the GIPR, Fig. 2.

The C terminal of GIP (∼residues 15 to 32) interacts with the extracellular domain (ECD) and ECL1 and, overall, resembles the interaction pattern of GLP-1 bound to the GLP-1R (16). The ECD engages GIP in the same way as prior crystallography studies of the isolated ECD of the GIPR indicated (22), and our studies provide a comprehensive understanding by showing that the ECL1 of the GIPR also contributes to the interaction with the C-terminal region of GIP, most notably His18GIP and Trp2965.36 (Fig. 1E). ECL1 adopts a more extended conformation in GIPR compared with that for both the GLP-1R (16) and the glucagon receptor (GCGR) (23), where an α helical structure is formed. The presence of Pro195GIPR, Pro197 GIPR, Pro199GIPR in the ECL1 prevents flexibility (Fig. 1E). With its side chain adopting a different rotamer, the hydroxyl group of Tyr1Tzp points toward Arg1902.67GIPR and Gln2203.33GIPR (Fig. 1D), and the cryo-EM map suggests there are water-mediated polar interactions among these residues (SI Appendix, Fig. S3). The extra interactions indicate that the sequence of tirzepatide may foster higher affinity and potency properties at the GIPR, Fig. 2.

Results and Discussion

Cryogenic Electron Microscopy (Cryo-EM) Structures of Tirzepatide in Complex with the GIPR and GLP-1R. To investigate the molecular basis for the pharmacological characteristics of tirzepatide, high-resolution structures of the GIPR in complex with native GIP (3.2-Å resolution) and of the GIPR and GLP-1R bound to tirzepatide (3.1-Å and 2.9-Å resolution, respectively) were determined by cryo-EM (Fig. 1A and SI Appendix, Figs. S1 and S2 and Table S1). The ligands were confidently modeled to the density maps (SI Appendix, Figs. S1 and S2), and residues 1 to 32 of both GIP and tirzepatide were resolved in the structures, comparable with the length of GLP-1 resolved in previously reported structures of the GLP-1R (16, 17). Importantly, the GIP/GIPR structure establishes the activation mechanism for this receptor, and similar to GLP-1 and glucagon in complex with their respective receptors, GIP adopts a continuous helical conformation (16, 18). The N terminus inserts into the transmembrane (TM) domain, making contacts with residues in TM1, TM2, TM3, TM5, TM7, and extracellular loop 2 (ECL2) through extensive polar and hydrophobic interactions (Fig. 1A and B). Of note, tyrosine in position 1 (Tyr1GIP) is buried in the TM core of the GIPR, hydrogen bonding with Gln2243.37 and making aromatic interactions with Trp2965.36 (Fig. 1B). The critical role of Tyr1 in GIP binding and receptor activation is supported by studies of truncated or mutant analogs of GIP (19, 20). Analogous results and conclusions with respect to the determinants of the GIP/GIPR interaction have recently been described (21). Consistent with its sequence similarity with the N-terminal portion of GIP, tirzepatide binds the GIPR in an analogous manner (Fig. 1A and C). The main chain of the N-terminal segment (∼residues 1 to 14) of tirzepatide largely overlaps with the equivalent segment of GIP (Fig. 1 D and E). Although most interactions of tirzepatide and GIP are similar, a key difference is the threonine at position 7 (Thr7Tzp) of tirzepatide (versus isoleucine in GIP) that provides hydrogen bonding with Arg1902.67GIPR (Fig. 1D), mimicking the interaction between the equivalent Thr13GLP-1 and Lys1972.67GLP-1R (17). Furthermore, the side chain of Arg1902.67GIPR is in a slightly different conformation compared to the GIP-bound structure, bringing it closer to Tyr1Tzp. With its side chain adopting a different rotamer, the hydroxyl group of Tyr1Tzp points toward Arg1902.67GIPR and Gln2203.33GIPR (Fig. 1D), and the cryo-EM map suggests there are water-mediated polar interactions among these residues (SI Appendix, Fig. S3). The extra interactions indicate that the sequence of tirzepatide may foster higher affinity and potency properties at the GIPR, Fig. 2.

The C terminal of GIP (∼residues 15 to 32) interacts with the extracellular domain (ECD) and ECL1 and, overall, resembles the interaction pattern of GLP-1 bound to the GLP-1R (16). The ECD engages GIP in the same way as prior crystallography studies of the isolated ECD of the GIPR indicated (22), and our studies provide a comprehensive understanding by showing that the ECL1 of the GIPR also contributes to the interaction with the C-terminal region of GIP, most notably His18GIP and Trp2965.36 (Fig. 1E). ECL1 adopts a more extended conformation in GIPR compared with that for both the GLP-1R (16) and the glucagon receptor (GCGR) (23), where an alpha helical structure is formed. The presence of Pro195GIPR, Pro197 GIPR, Pro199GIPR in the ECL1 prevents flexibility (Fig. 1E). With its side chain adopting a different rotamer, the hydroxyl group of Tyr1Tzp points toward Arg1902.67GIPR and Gln2203.33GIPR (Fig. 1D), and the cryo-EM map suggests there are water-mediated polar interactions among these residues (SI Appendix, Fig. S3). The extra interactions indicate that the sequence of tirzepatide may foster higher affinity and potency properties at the GIPR, Fig. 2.
Fig. 1. Cryo-EM structure determination of the GIPR/GIP, GIPR/tirzepatide, and GLP-1R/tirzepatide. (A) Overall structures of GIPR (orange)/GIP (yellow) (3.2-Å resolution), GIPR (magenta)/tirzepatide (blue) (3.1-Å resolution), and GLP-1R (slate blue)/tirzepatide (green) (2.9-Å resolution). Additional subunits of the complexes are colored as the following: GsαiN18, salmon; Gβ, dark green; Gγ, gray; Nb35, brown; ScFv16, violet-brown. (B, C) The interaction of GIP (B) or tirzepatide (C) and the TM domain of GIPR. Residues that are involved in interactions are shown as sticks, and the residues that contribute most significant interactions are labeled. Hydrogen bonds were labeled as dashes. (D) Difference of the residue on position 7 of GIP and tirzepatide. (E) The interaction of GIP and tirzepatide with the ECD and ECL1 of the GIPR.
sequences, and in all of these, Trp214ECL1 makes an important
1R-ECL1 conformation accommodates ligands with different
hydrogen bond forms between Tyr10GIP or Tyr10Tzp and the
Green) compared with GLP-1R (cyan)/GLP-1 (gray) (PDB: 6
from the ECL2 of the GLP-1R, and Arg299ECL2 does not interact with TZP. Residues that are involved in signi...

Differential binding of tirzepatide (TZP) versus GLP-1 at the GLP-1R. (Fig. 2A and B) GLP-1R/taspoglutide complex (25). The GLP-1R/Ex-P5 structure (24) (Fig. 2C) and the GLP-1R/GIPR structures reveal differences in their binding, consistently with the weaker affinity of GLP-1 for

The N terminus of tirzepatide presents another key feature which may contribute to its weaker affinity for binding the GLP-1R. Due to the bulkier side chain of Tyr1Tzp (versus His7GIP), Trp3065.36GLP-1R adopts an alternate rotamer which ensues steric conflict relative to the conformation of the GLP-1R/GLP-1 structure (Fig. 2C and SI Appendix, Fig. S7C). This change disrupts hydrogen bonding between Trp3065.36 and Asp372ECL3 that is observed in the GLP-1R/GLP-1 structure (Fig. 2C), similar to the scenario in the GIPR/GIP and GIPR/tirzepatide structures (SI Appendix, Fig. S7C). This specific conformation of Trp3065.36GLP-1R also changes conformations of many of the surrounding residues, including residues of the GLP-1R-ECL2 and Arg3105.40GLP-1R. Furthermore, the polar interaction between Arg3105.40 and Glu373ECL3 in the GLP-1R/GLP-1 structure is also lost in the tirzepatide bound structure (Fig. 2C). Together, polar interactions between the TM5 and ECL3 of the GLP-1R are lost due to the presence of tyrosine versus histidine at position 1. A previous report suggested that stabilization of ECL3 is required for full, unbiased agonism of the GLP-1R (29). Consistent with the loss of stabilizing interactions, the ECL3 in the GLP-1R/tirzepatide structure exhibits weaker density in the cryo-EM map. Notably, although fully buried in the pocket, the density for Tyr1Tzp

Arg299ECL2, which mediates polar interactions with various GLP-1R ligands (17), does not form such contacts with tirzepatide (Fig. 2B and SI Appendix, Fig. S7A). Mutation of Arg299ECL2 to alanine reduces the efficacy of GLP-1 for activating CAMP signaling (26, 27). On the other hand, the relative shift in the position of tirzepatide allows pi–pi stacking between Tyr10Tzp and Tyr1451.40GLP-1R, mimicking the interaction mode of oxyntomodulin by its equivalent Tyr10 residue (28) (Fig. 2B).

Despite some general similarity of the overall orientation of tirzepatide and GLP-1, detailed analyses of the GLP-1R/tirzepatide and GLP-1R/GLP-1 structures reveal differences in their binding, consistent with the weaker affinity of tirzepatide (10, 16). The Cα atoms of residues 2 to 9 of tirzepatide align well with the equivalent amino acids of GLP-1 (residues 8 to 15), all within 1 Å of each other. From Tyr10Tzp onward, the distance between their Cα atoms increases to about 2.2 Å within the subsequent helical turn at 2-aminoisobutyric acid (Aib)13Tzp and Tyr19GLP-1 (Fig. 2B). Although this is a modest difference, the shift in the position of tirzepatide results in weaker interactions with the ECL2 of the GLP-1R, which is implicated in determining the signaling profile of GLP-1R (26, 27).

Specifically, Arg299ECL2, which mediates polar interactions with various GLP-1R ligands (17), does not form such contacts with tirzepatide (Fig. 2B and SI Appendix, Fig. S7A). Mutation of Arg299ECL2 to alanine reduces the efficacy of GLP-1 for activating CAMP signaling (26, 27). On the other hand, the relative shift in the position of tirzepatide allows pi–pi stacking between Tyr10Tzp and Tyr1451.40GLP-1R, mimicking the interaction mode of oxyntomodulin by its equivalent Tyr10 residue (28) (Fig. 2B).

The N terminus of tirzepatide presents another key feature which may contribute to its weaker affinity for binding the GLP-1R. Due to the bulkier side chain of Tyr1Tzp (versus His7GIP), Trp3065.36GLP-1R adopts an alternate rotamer which ensues steric conflict relative to the conformation of the GLP-1R/GLP-1 structure (Fig. 2C and SI Appendix, Fig. S7B). This change disrupts hydrogen bonding between Trp3065.36 and Asp372ECL3 that is observed in the GLP-1R/GLP-1 structure (Fig. 2C), similar to the scenario in the GIPR/GIP and GIPR/tirzepatide structures (SI Appendix, Fig. S7C). This specific conformation of Trp3065.36GLP-1R also changes conformations of many of the surrounding residues, including residues of the GLP-1R-ECL2 and Arg3105.40GLP-1R. Furthermore, the polar interaction between Arg3105.40 and Glu373ECL3 in the GLP-1R/GLP-1 structure is also lost in the tirzepatide bound structure (Fig. 2C). Together, polar interactions between the TM5 and ECL3 of the GLP-1R are lost due to the presence of tyrosine versus histidine at position 1. A previous report suggested that stabilization of ECL3 is required for full, unbiased agonism of the GLP-1R (29). Consistent with the loss of stabilizing interactions, the ECL3 in the GLP-1R/tirzepatide structure exhibits weaker density in the cryo-EM map. Notably, although fully buried in the pocket, the density for Tyr1Tzp
and Trp306GLP-1R is weaker than other residues of tirzepatide for its binding pocket (SI Appendix, Fig. S7D), reflecting their flexibility in this less stable conformation.

**Dynamics of the Linker–Fatty Acid Moiety of Tirzepatide.** A key structural feature of tirzepatide is the C20 fatty diacid attached to the side chain nitrogen of Lys20Tzp via a linker of a L-γ-glutamic acid and two 8-amino-3,6-dioxaoctanoic acids (2) (Fig. 3A). In the tirzepatide-complexed GLP-1R and GIPR cryo-EM structures, both the linker–fatty acid moiety and the peptide C terminus (amino acids 33 to 39, hereinafter referred to as the Ct) appear disordered and were not resolved. Although structural aspects of acylated peptide interaction with the GLP-1R have not been previously resolved by crystallography (30), the recent cryo-EM structure of semaglutide (which contains a C18 diacid at position 20) bound to the GLP-1R revealed some density for the lipid modification (25). In this report on semaglutide, two conformations of linker–fatty acid chain were modeled, namely, one interacting with the ECD and one with the membrane (25).

In order to investigate the disposition of the lipid modification of tirzepatide within the peptide-receptor complexes, we...
Fig. 4. The C20 diacid fatty acid moiety of TZP impacts incretin receptor binding affinity. Mechanistic pharmacology studies investigating receptor binding and signal transduction were performed using TZP, an analog thereof lacking the lipid moiety (TZPΔC20), and a derivative that also contains histidine in place of tyrosine at position 1 (TZPΔC20,Y1H), (A) For each ligand, competitive inhibition of [125I]-GIP (1–42) binding was determined using membranes isolated from HEK293 cells expressing the human GIPR. Binding of TZP is shown to be equivalent to that of native GIP. Removal of the C20 diacid fatty acid chain increased the affinity of the ligand, while changing tyrosine to histidine weakened binding to the receptor. (B) Ligand-induced GTPγS binding of Gαs was performed using the GIPR-expressing membranes. Removal of the lipid moiety from TZP resulted in a modest increase in potency for inducing activation of the Gαs, versus TZP and GIP, but the TZPΔC20,Y1H analog showed both reduced efficacy and potency in comparison. (C) Agonist-stimulated cAMP production was measured in human GIPR expressing HEK293 cells. In line with the increase in binding affinity and potency to activate Gαs, absence of the lipid moiety led to increased potency for stimulating GIPR-mediated cAMP accumulation, while weaker activity was observed upon replacement of the tyrosine at position 1. (D) For the GLP-1R, competitive inhibition of [125I]-GLP-1(7–36)NH2 binding was determined using membranes isolated from HEK293 cells expressing the human GLP-1R. Binding of both TZP and TZPΔC20 is shown to be ~fivefold weaker than that of GLP-1, but changing tyrosine to histidine at position 1 restored the binding affinity to that of the native peptide. (E) Ligand-induced GTPγS binding of Gαs was performed using the GLP-1R-expressing membranes. Compared with GLP-1, TZP is shown to be a partial agonist at stimulating Gαs. Removal of the lipid moiety from TZP resulted in an increase in the efficacious response, with a slightly further elevation observed for the TZPΔC20,Y1H analog. (F) Agonist-stimulated cAMP production was measured in human GLP-1R-expressing HEK293 cells. The potency of TZP at stimulating cAMP accumulation is ~20-fold weaker than that of GLP-1. The absence of the lipid moiety improved potency and the nonlipidated parent peptide containing the histidine displayed activity that is indistinguishable from that of GLP-1. A derivative of glucagon-like peptide-1 containing tyrosine in place of histidine at position 7 (GLP-1H7Y) was used as a control. Data presented are representative of n ≥ 3 independent experiments. Summarized data are shown in SI Appendix, Table 2. log M; log Molar.

modeled in the C20 diacid conjugate, the Cts, and other unresolved atoms. A series of 1-µsec molecular dynamics (MD) explicit solvent simulations were then performed on models of tirzepatide in complex with either the GIPR or the GLP-1R in the membrane with the heterotrimeric G protein. The results revealed that the linker—fatty acid chain exists in multiple conformations (Fig. 3). Moreover, in the MD analyses, the lipid moiety makes a relatively low number of specific and persistent interactions with either receptor (Right panel of Fig. 3B). MD also indicated that an intramolecule hydrogen bond between the lipid chain and glutamine at position 24 of tirzepatide is more prevalent with the GIPR (~40% of the simulation time) than in the GLP-1R complex (~18% of the simulation time, Left panel of Fig. 3B). Overall, intermittent hydrogen bonding of the lipid moiety with the receptor is more distributed and prevalent in the GIPR than in the GLP-1R (Right panel of Fig. 3B). Consistent with these observations, the diacid chain in the GIPR/tirzepatide complex was found to be more compact than in the bound GLP-1R complex, as indicated by its mean radius of gyration (6.8 Å for the GIPR versus 7.6 Å for the GLP-1R) (Fig. 3C), while maintaining similar distributions for solvent accessible surface area and polar surface area of the lipid moiety (SI Appendix, Fig. S8). MD snapshots (Fig. 3D) demonstrate conformational diversity of tirzepatide in both receptors.

Pharmacological Basis for the Function of Tirzepatide. From the analyses of the cryo-EM structures of tirzepatide in complex with both receptors and the hypotheses proposed upon
performing the MD simulations, a series of peptide analogs was synthesized to investigate the molecular basis underlying the pharmacological activity of tirzepatide. This was a knowledge-based design approach that deconstructed tirzepatide to evaluate its receptor binding and signaling properties. We note that the albumin-binding propensity of fatty acid-modified peptides can confound a pharmacological comparison of molecules, given the common use of albumin and serum as nonspecific blocking agents in biological assays. Therefore, to obviate this, entirely albumin-free assays supplemented with bovine casein or bacitracin were used to prevent nonspecific binding (10).

Competition binding assays revealed that removal of the lipidic side chain (TZPΔC20,Y1H) yields a ligand with approximately fourfold greater affinity than tirzepatide at the GIPR (Fig. 4A). The fatty acid modification feature of tirzepatide is necessary for the sustained pharmacokinetics of the molecule (1). The binding assay results indicate that a higher affinity parent peptide is an important contributor to the overall affinity of tirzepatide because it allows the addition of the fatty acid moiety that ultimately results in tirzepatide having equal affinity to that of GIP, a characteristic needed for its imbalanced potency pharmacology. Similar to the effect on affinity, removal of the lipid improved the potency of the ligand for stimulating GIPR-mediated activation of Gs (Fig. 4B) and receptor-induced accumulation of intracellular cAMP (Fig. 4C). Consistent with the therapeutic aim of a dual GIP/GLP-1 receptor agonist possessing activity at the GIPR that is similar to GIP, the amino acid sequence of tirzepatide contains many of the same residues that are found in GIP, especially those located within the N-terminal half of the ligand that make critical interactions with the GIPR binding pocket (Fig. 1). In particular, examination of the cryo-EM structures revealed the potential importance of the N-terminal tyrosine of both GIP and tirzepatide in interacting deep near the bottom of the receptor core (Fig. 1). In agreement with this model, changing tyrosine to histidine (TZPΔC20,Y1H), to match the first position of GLP-1, weakened the binding affinity by ∼20-fold (Fig. 4A). Similarly, this substitution also decreased efficacy for Gs activation and cAMP accumulation (Fig. 4B and C). These results point to the importance of the native tyrosine at this position for maintaining GIPR affinity and full agonism.

By contrast with tirzepatide mimicking the actions of GIP, its pharmacology at the GLP-1R differs from that of GLP-1. Previous studies showed that the affinity of tirzepatide for binding the GLP-1R is ∼fivefold weaker than that of GLP-1, manifesting in weaker potency and reduced efficacy in stimulating Gs activation, decreased potency in cAMP signaling, and little ligand-induced β-arrestin recruitment (10). From a therapeutic standpoint, the bias toward cAMP signaling versus β-arrestin recruitment may be advantageous for the GLP-1 component of tirzepatide as it fosters less agonist-induced desensitization. The findings in this current report further highlight the pharmacological differences of tirzepatide at the GLP-1R versus the GIPR. For instance, as opposed to the increase in affinity for the GIPR that occurred upon removal of the lipid, the affinity of tirzepatide for binding the GLP-1R was unaffected by the loss of the side chain (Fig. 4D). However, the nonacylated analog displayed higher efficacy in GLP-1R-stimulated Gs activation (Fig. 4E) and stronger potency in cAMP accumulation (Fig. 4F). Additionally, changing the N-terminal tyrosine to histidine in the nonacylated analog further improved potency, resulting in a ligand that is close to functionally equivalent to GLP-1 in these assays (Fig. 4E and F). Although the influence of the noncognate tyrosine in combination with the presence of the acyl modification reduces the efficacy of GLP-1R-stimulated Gs signaling, this pharmacological profile remains sufficient to fully enhance insulin secretion and reduce hyperglycemia through the GLP-1R, as previously demonstrated by tirzepatide in cultures of pancreatic islets and glucose tolerance tests of Gipr null mice (1).

For class B G protein coupled receptors (GPCRs), including the GIPR and the GLP-1R, the N-terminal ECD is a unique structural feature that is implicated in the mechanism of ligand recognition. Interestingly, during the processing of the GLP-1R/tirzepatide cryo-EM data, three-dimensional (3D) classification revealed a unique class of GLP-1R/G protein complexes that showed no density for tirzepatide, a totally disordered ECD, and a wide-open extracellular pocket of the TM domain (SI Appendix, Figs. S2 and S9). Given that tirzepatide has nanomolar affinity for binding the full-length GLP-1R (Fig. 4D), and a saturating amount of tirzepatide was added during the sample preparation, the presence of apo complexes points to the hypothesis that tirzepatide engages with the GLP-1R TM bundle less stably than the ECD, consistent with the two-step model proposed for class B GPCRs (31). Therefore, to directly assess the contribution of ECD binding to ligand affinity, we purified the ECDs of both receptors and measured direct binding of peptide ligands using surface plasmon resonance. Ligands were found to bind the ECD of the GIPR with affinities in the low micromolar range, specifically tirzepatide (equilibrium constant [K_D] = 4.2 μM) and tirzepatideΔC20 (K_D = 1.7 μM) indicating that the enhanced receptor affinity of tirzepatideΔC20 is principally independent of ECD binding for the GIPR (SI Appendix, Fig. S10). By contrast, binding to the GLP-1R ECD was of substantially higher affinity for tirzepatide (K_D = 23 nM) versus tirzepatideΔC20 (K_D = 111 nM) (SI Appendix, Fig. S10), suggesting that the enhanced affinity delivered by the lipid moiety may be accounted for by interactions with the ECD of the GLP-1R.

Assays of non-G protein signaling were then used to further investigate the divergent pharmacology of tirzepatide at the GLP-1R. In line with previous results showing low efficacy/fractional agonism of tirzepatide-induced recruitment of β-arrestin to the GLP-1R (10), tirzepatide demonstrated a similar profile in recruiting G protein-coupled receptor kinase 2 (GRK2) (Fig. 5A and B), which helps terminate signaling by phosphorylating the receptor to enable binding of β-arrestins (32). Studies of the tirzepatide analogs in both assays revealed a modest increase in recruitment efficacy of the nonacylated parent peptide, and nearly full efficacy was achieved with the ligand that also contains the tyrosine-to-histidine replacement (Fig. 5A and B). Since agonist-induced receptor internalization is often mediated by β-arrestin trafficking, GLP-1R internalization by the analogs was assessed using the N terminus SNAP-tag system. In these experiments, the potency and efficacy of tirzepatide to induce GLP-1R internalization were both greatly increased in the absence of the lipid (Fig. 5C). The ligand with the histidine at position one (TZPΔC20,Y1H1H) showed a further slight improvement, resulting in equipotency to GLP-1 in the assay (Fig. 5C).

To extend these findings beyond the heterologous cellular systems, fluorescently labeled peptides were synthesized and used in orthogonal experiments to visualize ligand-induced receptor internalization in pancreatic islets. In these studies, GLP-1ΔC64V, tirzepatideΔC20,Y1H1H, or (D-Ala2)GIPRΔC20,Y1H1H were incubated in static cultures of islets isolated from wild-type or Glp-1R null mice. Imaging by confocal microscopy showed that treatment with labeled GLP-1 (Fig. 5D) or tirzepatideΔC20,Y1H1H (Fig. 5E) resulted in a portion of the ligand appearing
Biased pharmacology of TZP at the GLP-1R occurs through a composite effect on signaling efficacy by the N-terminal tyrosine and the C20 diacid fatty acid moiety. Mechanistic pharmacology studies investigating receptor binding and signal transduction were performed using TZP, an analog thereof lacking the lipid moiety (TZPΔC20), and a derivative that also contains histidine in place of tyrosine at position 1 (TZPΔC20,Y1H). Non-G protein signaling by TZP at the GLP-1R was investigated using assays for GRK2 (A) and β-arrestin (B) recruitment. In both systems, TZP is shown to be a weak, partial agonist in comparison to GLP-1. Removal of the C20 diacid fatty acid moiety improved the responses, and the absence of the lipid moiety in combination with replacing tyrosine with histidine resulted in activity that is nearly fully efficacious. (C) Ligand-induced internalization of the GLP-1R was assessed using changes in the cell surface presentation of SNAP-tagged receptor in HEK293 cells. Relative to GLP-1, TZP is shown to be a weak, partial agonist at inducing internalization of the GLP-1R. Consistent with restoring β-arrestin recruitment, the TZPΔC20 and TZPΔC20,Y1H derivatives are shown to proportionally improve ligand-induced receptor internalization. A derivative of glucagon-like peptide-1 containing tyrosine in place of histidine at position 7 (GLP-1H7Y) was used as a control. Data presented are representative of n ≥ 3 independent experiments. Summarized data are shown in SI Appendix, Table 2. (D–L) Representative confocal images of pancreatic islets labeled with fluorescently tagged GLP-1, TZP, TZPΔC20,Y1H, or GIP. Red Fluorescence (or green fluorescence for GIP) was detected following incubation of islets from wild-type (D, G, J) or Glp-1r–/– (F, I, L) mice with 30 nM of GLP-1AF647, TZPAF647, TZPΔC20,Y1H-AF647, or (D-Ala2)GIPAF488 for 30 min. (E, H, and K) An additional set of islets from wild-type mice were preincubated with 2 μM GLP-1R antagonist exendin-4(9-39) prior to treatment with the fluorescently labeled ligands. Nuclei are stained in blue with Hoechst 33342. log M; log Molar. (Scale bars, 10 μm.)
intracellularly as punctate fluorescent signal accumulated in the cytoplasm and perinuclear regions of islet cells. Intracellular fluorescence intensities for labeled GLP-1 and tirzepatide were 104.5 ± 7.5 SEM (n = 22) and 85.3 ± 5.9 SEM (n = 16), respectively. However, the intracellular fluorescence intensity in islets incubated with tirzepatide was only 46.0 ± 3.6 SEM (n = 30). As controls, islets pretreated with the GLP-1R antagonist exendin-4 (30, 39) (Fig. 5 E, H, and K) or from GLP-1R null mice (Fig. 5 F, I, and L) showed negligible intracellular fluorescence (intensities of ≤3.0 at n ≥ 13), supporting a mechanism that lipid modification in general does not prevent ligand internalization. Also, we speculate that a lack of apparent GIPR-mediated ligand internalization is due to differences in the magnitude of GIP internalization, as has been previously reported (10, 33), and/or the sensitivity of the method. Overall, the limited ability of tirzepatide to cause GLP-1R desensitization through GRK2/β-arrestin recruitment is consistent with its inability to induce GLP-1R internalization.

Together, the studies in this report investigated the molecular mechanism and structural determinants of the unique pharmacological profile of tirzepatide. Summation of the overall findings points to a model whereby biased agonism at the GLP-1R is driven by multiple mechanisms. Key interactions with the N terminus of tirzepatide are implicated in coordinating allosteric transitions essential for receptor activation, as is the case for other biased ligands (24, 29, 34). Consistent with prior studies (35, 36), we observed that the exendin-4 homologous sequence in the C terminus of tirzepatide facilitates a high-affinity interaction with the GLP-1R relative to the GIPR. By the nature of the classic two-step mechanism for class B peptide binding (31), the ECD-driven affinity of tirzepatide may engender a pharmacological opportunity for N-terminal residue modification while maintaining full-length receptor binding affinity. Modification of the N terminus of canonical class B GPCR ligands is well demonstrated to alter transducer efficacy (14, 37–39). Recent insights into class B GPCR activation suggest a complex, multistep mechanism for activation of heterotrimeric G proteins (40, 41), but the mechanism is less clear with respect to β-arrestin recruitment. We have previously observed that tirzepatide exhibits partial agonism for G protein activation at the GLP-1R (10), and this may represent a central mechanism of biased agonist pharmacology.

In conclusion, peptide therapeutics represent an increasingly important modality for drug discovery (42). Often, fatty acid modification is utilized as an effective approach for enhancing the in vivo half-life of peptides. This occurs in large part because binding of acylated peptides to serum albumin shields them from proteolysis and excretion. We demonstrate that peptide structure activity–relationships (SAR) are influenced/determined by acylation in a receptor and signal transduction dependent manner. As such, the pharmacological profile of tirzepatide is combinatorially determined by both the peptide sequence and the presence of the lipid moiety. Uniquely, the lipid modification of tirzepatide in combination with tyrosine 1 is a key feature for the reduced efficacy of tirzepatide for GRK2 and β-arrestin recruitment and consequently internalization by the GLP-1R. Surprisingly, the effects of acylation are differential in that the nonpeptidic portion of the molecule reduces GIPR affinity but diminishes GLP-1R efficacy. The realization that SAR for both peptide and lipid modifications can drive subtle but potentially significant pharmacological effects (partial or biased agonism) suggests that the design of new therapeutics should encompass a wider swath of pharmacological, structural, and computational approaches to understand the complex interplay between receptors and acyl-peptide drugs.

**Methods**

**Ligands.** All peptides were synthesized at Eli Lilly and Company using a standard solid-phase peptide synthesis methodology employing an Fmoc protecting group strategy, using Rink-amide resins with a loading of 0.35 to 0.88 mmol/g. Analogs containing linker-fatty acid modifications were accessed by incorporation of an Fmoc-Lys(Mtt)OH residue at the appropriate position, in tandem with Boc-protection of the N-terminal residue. Orthogonal removal of the Mtt protecting group was achieved through treatment with 30% hexafluoroisopropanol in dichloromethane, prior to stepwise synthesis of the linker-fatty acid group with standard Fmoc chemistry. Following completion of the synthesis, peptides were cleaved from the resin by treatment with Trifluoroacetic acid (TFA)/water/triisopropylsilane/1,2-ethanediol (EDT) (85:5:5:5) for 2 h, followed by precipitation and washing with cold ether. Peptides were purified by reverse phase high-performance liquid chromatography (RP-HPLC) using gradients of acetonitrile and water containing 0.1% TFA, to ≥95% purity. Selected analogs were fluorescently labeled at their C termini, first by incorporation of an additional C-terminal Fmoc-Lys(Mtt)OH residue, which was similarly deprotected and functionalized with propargyl-PEG2-acid (Bodiapharm), prior to synthesis of the remaining sequence and purification as described above. The resulting alkyne-tagged peptide precursors were then conjugated to AF647 AAside (Click Chemistry Tools) or AF488 AAside (Sigma Aldrich) using Cu-catalyzed azide-alkyne cycloaddition chemistry in water/dimethylformamide (1:1) and repurified by RP-HPLC. The positive allosteric modulators (PAMs) are as follows: LS354351724 (1-(4-

**Constructs and Insect Cell Expression.** The human GIPR (residues 24 to 466) and GLP-1R (residues 24 to 422) cDNAs were subcloned into the pFastBac vector containing an N-terminal FLAG tag and a 3C protease site. Sf9 cells were infected with P2 virus produced according to the manufacturer's protocol to produce GIPR- and GLP-1R-expressing cell pellets. The human Gαs subunit was modified with its 1 to 25 residues being replaced by 1 to 18 residues of the human Goβ1 at its N terminus to allow the binding of a single-chain variable fragment scFv16 as a stabilizing partner (43). This construct, named GαsXN18, was cloned into pVL1392. Human Gp1 and Gγ2 were cloned into pFastBac Dual on the same vector. The P2 virus stocks were produced according to the manufacturer's protocol. Hi5 cells were infected with both GαsXN18 and Gβ1-Gγ2 viruses to produce the heterotrigemeric GsN18 protein cell pellets.

**Complex Formation and Purification.** The GIPR/GIP complex and the GIPR/tirzepatide and GLP-1R/tirzepatide complexes were formed and purified with similar strategies and are therefore described together. Steps and details that are specific to an individual sample are noted. Heterotrigemeric GsN18 was purified by Ni-affinity column and ion-exchange chromatography (44). scFv16 and Nb35 were produced as described previously (43, 44). Receptor/G protein complexes (referred to as the complex(es) in the following text) were formed in membrane. To prepare the complex samples, pellets of S9 cells expressing the respective receptor were lysed, and membrane samples were collected and washed. The complexes were formed by incubating purified molar excesses of heterotrigemeric GsN18, Nb35, scFv16, and 10 μM of the respective peptide (GIP or tirzepatide) with membranes overnight. For the GIPR/tirzepatide and GLP-1R/tirzepatide samples, 10 μM LS3556672 and LS3451217 were added, respectively. Samples were solubilized in buffer comprised of 1% DDM, 0.5% 3-(3-Cholamidopropyl)dimethylammonio)1-propanesulfonate hydrate, 0.2% cholesteryl hemisuccinate (CHS), 30 mM Hepes (pH 7.8), 150 mM NaCl, 30% glycerol, 25 μM tris(2-carboxyethyl)phosphate, 2.5 mg/mL leupeptin, 0.16 mg/mL benzamidine, 1 μM peptide, and 2 μM of the respective PAM for the GIPR/tirzepatide.
and GLP-1R/tirzepatide sample. Complexes were then purified by affinity chromatography using anti-FLAG M1 resin. For GIPR/GIP and GIPR/tirzepatide purification, the resin was washed with buffers containing high (1% DDM, 0.5% CHAPS, 0.2% CHS) and low (0.1% DDM, 0.05% CHAPS, 0.02% CHS) detergent concentrations, alternatively. Other components of the buffer were the same, as follows: 30 mM Hepes (pH 7.8), 150 mM NaCl, 10% glycerol, 25 μM TCEP, 1 μM tirzepatide, and 2 μM of the PAM. The volume used was 12 column volumes for each buffer. For the GLP-1R/tirzepatide sample, the resin was washed with 10 column volumes of 0.1% DDM, 0.05% CHAPS, 0.2% CHS, 30 mM NaCl, pH 7.8, 150 mM NaCl, 10% glycerol, 25 μM TCEP, 1 μM Tirzepatide, and 2 μM of the PAM. After washing, the sample was exchanged in a step-wise manner in buffer comprised of 30 mM Hepes (pH 7.5), 150 mM NaCl, 2.5 mM CaCl2, 1 μM of the respective peptide, 2 μM of the respective PAM, 10 μM TCEP, 0.25% lauryl maltose neopentyl glycol (MNG; NG310 Anatec), 0.25% GDN101 (Anatec), 0.048% 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-1'-rac-glycerol (POPG; Avanti), and 0.03% cholesterol (Sigma-Aldrich). Complexes were eluted and further purified by size-exclusion chromatography using a Superdex S200 10/300 GL column with running buffer of 30 mM Hepes (pH 7.5), 150 mM NaCl, 1 μM of the respective peptide and 2 μM of the respective PAM, 100 μM TCEP, 0.015% MNG, 0.005% GDN101, 0.00192% POPG, and 0.0012% cholesterol. The fractions for monomeric complexes were collected and concentrated individually for electron microscopy experiments.

Cryo-EM Data Acquisition and Processing. Samples of 3.5 μl of purified complexes at a concentration of ~10 mg/ml were applied to glow-discharged holey carbon grids (Quantifoil R1.2/1.3, 200 mesh) and subsequently vitrified using a Vitrobot Mark IV (Thermo Fisher Scientific). Specimens were visualized using a Titan Krios electron microscope (Thermo Fisher Scientific) with an energy filter operating at 300-kV accelerating voltage using a K3 Summit direct electron detector (Gatan, Inc.) in counting mode. Statistics for the data collection are indicated in SI Appendix, Table S1.

Data processing was performed in Relion3.1 (45). Dose-fractionated image stacks were subjected to beam-induced motion correction using MotionCor2 (46). Contrast transfer function (CTF) parameters for each micrograph were determined by Gctf (47). Manual selection of micrographs based on their quality and CTF estimated resolution was performed prior to subsequent steps. Particle selection with two-dimensional (2D) and 3D classifications were performed on a binned dataset with a pixel size of 1.64 Å. Semi-automated particle selection was carried out using a template from a previously reported GLP-1R/GLP-1/Gs/Nb35 complex (16); these particles were subjected to 2D and 3D classification. After 3D classification, classes of particles that generated the best 3D maps were selected, and unbinned versions of these particles were used as the input for 3D autorefinement. Bayesian polishing and CTF refinement (48) were applied to further improve the map. The flow charts for individual samples are shown in SI Appendix, Figs. S1 and S2. Reported resolution is based on the gold-standard Fourier shell correlation using the 0.143 criterion (SI Appendix, Figs. S1 and S2).

Model Building and Refinement. Initial model building was done using by rigid-body fitting of the reported GLP-1R/GLP-1/Gs/Nb35 structure (RCSB Protein Data Bank code 6WCB). The sequence was mutated to match GIPR, GIP, or tirzepatide when applicable in respective models. The starting model was then subjected to iterative rounds of manual and real space refinement in Coot (49, 50) and Phenix (51), respectively. Final models were visually inspected for general fit to the maps, and geometry was further evaluated using Molprobity (52). Final refinement statistics for the models are summarized in SI Appendix, Table S1.

Atomic coordinates and the cryo-EM density maps have been deposited in the Protein Data Bank (PDB) and The Electron Microscopy Data Bank (EMDB). The accession numbers are as follows: GIPR/GIP (PDB: 7RA3; EMDB: EMD-24334); GIPR/tirzepatide (PDB: 7R8T; EMDB: EMD-24401); GLP-1R/tirzepatide (PDB: 7RGP; EMDB: EMD-24453); and GLP-1R apo form (PDB: 7RGG; EMDB: EMD-24445).

MD Simulations. Missing receptor loops and side chains were added to both cryo-EM structures of the tirzepatide:GIPR:G protein and tirzepatide:GLP-1R:G protein complexes reported herein, using the homology modeling process and 3D and peptide builders in MOE (Molecular Operating Environment). The linker-fatty acid lipid chain conjugated to Lys20Tzp and the C-terminal 33 to 39 residues, which were not observed in the cryo-EM structures, were modeled in extended conformations and placed away from the receptors as the initial structure models in order to avoid introducing artificial biased interactions with the receptors. The complex structures were further energy minimized with restrained heavy atoms using Schrödinger software (version 202.3). The transferable intermolecular potential with 3 points water and the phosphatidylcholine membrane were then added to the complex systems for running MD. The membrane positions were set to the receptor residues 136 to 159, 172 to 193, 215 to 239, 258 to 280, 294 to 318, 339 to 362, and 372 to 395 in GIPR; and 143 to 165, 179 to 200, 225 to 249, 268 to 290, 304 to 329, 350 to 373, and 381 to 405 in GLP-1R. The alpha carbon atoms of the TM domain and intracellular G protein components were harmonically restrained (0.1 kcal/mol Å2), with the ECDs of the receptors, the peptides, and the modulators unrestrained. Systems contained 220K atoms, and the simulations were run with Desmond MD package using the OPLS3e force field (53). An analysis was performed dismissing the first 10 nsec of the trajectory. The radius of gyration, hydrogen bonds, and polar area were monitored during the simulations. All MD simulations and analyses were carried out on V100 Nvidia graphics processing unit using Schrodinger software (version 2020.3).

In Vitro Pharmacology. Recombinant human GIPR and GLP-1R expressing cell lines, cAMP accumulation assays, [35S]GTPγS binding assays, NanoBRET β-arrestin 1 recruitment, and [125I]-GLP-1(7-36)NH2 and [125I]-GIP (1-42) radioligand binding studies were conducted exactly as described in reference 10.

To assess ligand-induced receptor internalization, HEK293 cells expressing SNAP-GIP-1R were labeled with 100 nM TagLite SNAP-Lum4-Tb (donor), washed, and incubated in Opti-MEM containing 100 μM fluorescein-O’ acetic acid (acceptor). Varying concentrations of the ligands were then added, and mixtures were incubated at 5% CO2/37°C. Data were collected using an EnVision plate reader. Percent internalization compared to maximal GLP-1 was plotted versus the concentration of ligand. Additional experimental details for the above procedures were previously reported (10). Data for all assays were fit to the four-parameter logistic model in Genedata Screener 17 or GraphPad Prism 9 software.

ECO Binding Assay. The isolated ECDs of human GIPR (amino acids 26 to 138) and GLP-1R (amino acids 24 to 145) were expressed as 6His-tagged secreted proteins in CHO cells. DNA encoding each protein was transfected into CHO cells for expression. After expression, the proteins were purified by affinity chromatography (Hi-Trap Ni, Cytiva) followed by size exclusion chromatography using a HiLoad 26/60 Superdex 75pg column (Cytiva) with PBS buffer. Fractions were analyzed by sodium dodecyl-sulfate polyacrylamide gel electrophoresis, and fractions meeting purity criteria were pooled, then 0.22 μm filtered. Surface plasmon resonance measurements were made using a Biacore 1200 (Cytiva) and analyzed using T200 Evaluation Software Version 3.1. Receptor ectodomain proteins were covalently immobilized (~250 resonance units) on Sensor Chip CM4 BR1005S using the Amine coupling Immobilization Wizard in the Biacore 1200 Control Software Version 2.0.2. Running buffer was HBS-EP (10 mM Hes, 150 mM NaCl, 3 mM EDTA, 0.05% P20 [pH 7.6]; Teknova). Concentration series for each sample were made by serial dilution in running buffer. The samples were injected for 150 sec at a 30 μL/min flow rate, followed by 300 sec of dissociation. The surface was regenerated between samples with 10 mM glycine (pH 1.7).

Labeling of Pancreatic Islets. Mouse and rat islets were isolated as previously described (56), allowed to recover for 48 h in RPMI 1640 media (Gibco) containing 10% fetal bovine serum (FBS), and then adhered to imaging assay plates using Cell Tak cell adhesion (Corning) in RPMI 1640 media containing 0.5% FBS for 120 min at 5% CO2/37°C. For receptor specificity, during the last hour of the adherence phase, a portion of islets were incubated with 2 μM oxidin42039 to assess GLP-1R binding. Islets were labeled with fluorescent ligands (10 to 30 nM) in assay buffer consisting of Hank's balanced salt solution with 0.1% casein for 30 min at 5% CO2/37°C. Background fluorescence was determined on islets
incubated with assay buffer only. Following labeling, islets were rapidly washed two times with PBS to remove unbound fluorescence then immediately fixed in 4% paraformaldehyde, 0.1% Tween-20, and 0.4 µg/mL Hoechst 33342 for 30 min at room temperature. The mouse islets were imaged using a Zeiss LSM800 confocal microscope with 63x oil objective. For the rat islets, after fixation, islets were stained with 125 nM AequorFluo488 Phalloidin (Thermo Fisher Scientific) for 20 min at room temperature to detect the cell membrane. Then, images were taken with an Airyscan on the LSM800 and deconvoluted using Zen software (Blue edition 2.3.2, Zeiss). Quantitation was also done using Zen software. The intracellular fluorescence intensity of individual islet cells was measured in the perinuclear region using a circular, 5-µm-diameter tool. The intensity values were corrected for background by subtracting fluorescence intensities recorded from vehicle-treated islets. Data were sampled from at least four individual islets from two to five individual islet images. Data are reported as mean ± SEM.

Data Availability. Coordinates and cryo-EM maps data have been deposited in Protein Data Bank (PDB) and Electron Microscopy Data Bank (EMDB) (PDB: 7RA3, EMDB: EMD-24334) (PDB: 7RB7, EMDB: EMD-24401) (PDB: 7RPK, EMDB: EMD-24453) (PDB: 7R9G, EMDB: EMD-24445).

ACKNOWLEDGMENTS. We thank Samreen Syed, Jim Ficorilli, Betty Chau, Anthony Ransdell, Andrea Geiser, Kate Lansu, and Ricardo Samms for technical assistance and critical discussions of the content of the manuscript. We also thank Ruth Gimeno, Axel Haupt, and Jude Onyia for their long-standing support of the project. The cryo-EM data were collected at Nanomaging Service and Oregon Health & Science University.

Author affiliations: 1Molecular Pharmacology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285; 2BioTechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285; 3Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285; 4Lilly Biootechnology Center San Diego, San Diego, CA 92121; 5Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285; and 6Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285. Data Availability. B.S., F.S.W., D.F., J.A.F., A.D.S., C.S., L.D., T.M.S., J.D.D., F.A.M., E.A., P.J.E., B.K.K., and K.W.S. designed research; B.S., F.S.W., D.F., C.S., T.M.S., J.D.D., J.W.C., F.A.M., and E.A. performed research; J.A.F., R.A.B., and A.B.B. contributed new reagents/analytic tools; B.S., F.S.W., D.F., G.C., M.V., J.D.D., A.D.S., C.S., L.D., T.M.S., J.D.D., F.A.M., E.A., J.S.M., T.S.K., M.P.C., B.K.K., and K.W.S. analyzed data; and B.S., F.S.W., M.P.C., B.K.K., and K.W.S. wrote the paper.